LAGUNA HILLS, Calif., Feb. 12, 2025 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, ...
December 10, 2010 (San Antonio, Texas) — "Nobody knows whether patients with HER2-positive ductal carcinoma in situ (DCIS) have increased local recurrence of disease," said Lia Halasz, MD, a radiation ...
DCIS, often called Stage Zero breast cancer, is the earliest stage and often diagnosed via mammogram, with no symptoms. In most cases, DCIS will not turn into a life-threatening tumor, but doctors ...
Improving patient understanding of GEP test results (IMPARTER4): An RCT. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.
Study findings highlight the importance of follow-up screening and the value of patient communication among DCIS, or ductal carcinoma in situ, survivors. A study published in 2023 sheds light on how ...
October 27, 2009 — Women with low- to intermediate-grade ductal carcinoma in situ (DCIS) with margins 3 mm or wider had an "acceptably low rate" of ipsilateral breast events 5 years after excision ...
DCIS is a pre-invasive breast cancer condition with uncertain progression, often leading to aggressive treatment despite its "stage 0" classification. The lack of definitive guidance for DCIS ...
Delaying radiation therapy too long after surgery significantly increases the risk of recurrent tumors in women treated for very early, or what is referred to as "stage 0," breast cancer, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results